News – Page 1061 – Endpoints News

SIGN UP

Pfizer inks deal with startup Adapsyn to search microbes for novel compounds

8 years ago

Boasting a late-stage Botox me-too, Evolus files for $75M IPO

8 years ago

Billionaire-backed Juvenescence primes the anti-aging pipeline pump with a $12M seed round

8 years ago

Axovant: That positive p-value we reported yesterday? Um, we screwed that up too

8 years ago

On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product ...

8 years ago

After bumpy 2017, Celgene CEO says taking risk is the only way forward

8 years ago

Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

8 years ago

Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars

8 years ago

Teva inks $200M global licensing deal with migraine rival Alder

8 years ago

Axovant shares blasted as Vivek Ramaswamy's premier drug proves worthless, second drug misses key goal

8 years ago

Novo Nordisk tries to tackle Ablynx and bring it into the fold with a $3B buyout offer, but the biotech keeps saying ...

8 years ago

Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran

8 years ago

Developing a Sanofi cast-off, Impact Biomedicines now subject of $7B Celgene acquisition deal

8 years ago

Pfizer is axing its neurosciences division, laying off 300 and discarding new drugs

8 years ago

After resisting a push to the auction block, Acorda preps for a sale and shares shoot up — report

8 years ago

J&J does Alzheimer's gene therapy deal, along with 14 other new collaborations

8 years ago

Sanuj Ravindran to lead PellePharm as CEO; Paul Hastings leaves OncoMed; Moderna taps John Mendlein as president

8 years ago

Lundbeck partners with Vanderbilt on new schizophrenia drug; Peregrine officially renamed Avid BioServices in pursuit ...

8 years ago

Kala Pharma shares damaged by mixed data from PhIII dry eye program

8 years ago

China's KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly

8 years ago

Neurodegeneration star Denali nabs a cash-rich, $1B-plus Alzheimer’s partnership with Takeda

8 years ago

Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval

8 years ago

Faheem Hasnain and his ex-Receptos team launch a new biotech with $100M and a twist on the old biotech model

8 years ago

SVB's crystal ball points to big money biotech IPOs, downshift in the torrid pace of venture investing

8 years ago

First page Previous page 1058 1059 106010611062 1063 1064 Next page Last page